Tyrosine kinase inhibitor induced pancreatitis

Abstract

Sorafenib and sunitinib are oral tyrosine kinase inhibitors, commonly used in the treatment of metastatic renal cell carcinoma. Known adverse events associated with tyrosine kinase inhibitors include hypertension and palmarplantar erythrodysesthesia. We report two cases of acute pancreatitis associated with tyrosine kinase inhibitors.

Keywords: Pancreatitis; sorafenib; sunitinib; tyrosine kinase inhibitor.